<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00645021</url>
  </required_header>
  <id_info>
    <org_study_id>A5351029</org_study_id>
    <nct_id>NCT00645021</nct_id>
  </id_info>
  <brief_title>Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug</brief_title>
  <official_title>A Phase 1, Open-Label, Parallel Group, Multiple-Dose Study To Evaluate The Pharmacokinetics, Safety And Toleration Of CP-945,598 Administered To Subjects With Impaired And Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CP-945,598 is eliminated following extensive metabolism. Decrease hepatic function can affect
      its elimination from the body via metabolism. This study will therefore compare the
      pharmacokinetics (time course of drug concentrations in the body), safety, and tolerability
      of CP-945,598 in patients with mild and moderate hepatic impairment and healthy control
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of drug and metabolite concentrations in serum collected at various times over 24 hour dosing interval on Days 1 and 14, before daily dose on days 5-7, 13, following stopping of drug treatment on days 15-18, 21, 28, and 35</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety laboratory tests (chemistry, hematology, urinalysis) on days 0, 7, 15, 35</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event monitoring throughout duration of the study</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs (blood pressure, heart rate and respiratory rate) on days 1, 7, and 14</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECGs on Days 1, 7, and 14</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Obesity</condition>
  <condition>Hepatic Insufficiency</condition>
  <arm_group>
    <arm_group_label>Mild hepatic function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate hepatic function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal hepatic function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-945,598</intervention_name>
    <description>Administration of CP-945,598 in subjects with mild hepatic function</description>
    <arm_group_label>Mild hepatic function</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-945,598</intervention_name>
    <description>Administration of CP-945,598 in subjects with moderate hepatic function</description>
    <arm_group_label>Moderate hepatic function</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-945,598</intervention_name>
    <description>Administration of CP-945,598 in subjects with normal hepatic function</description>
    <arm_group_label>Normal hepatic function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy:Matched for age (± 5 years), weight (± 10 kg), and gender (±2 subjects per
             gender)

          -  Subjects with hepatic disease: 1. mild impairment (child-pugh score 5-6), moderate
             (child-pugh score 7-9). 2. stable hepatic disease: no changes in the last 30 days. 3.
             stable dose of medication and/or treatment.

        Exclusion Criteria:

          -  All subjects: Non-prescribed use of drugs of abuse/recreational drugs; recent
             treatment with experimental drugs or herbal experiments; ECG and blood pressure
             falling outside of protocol-specified limits; history of regular tobacco use exceeding
             protocol-specified limits

          -  Normal subjects: medically important health conditions; recent use of prescription or
             non-prescription medications; history of regular alcohol use exceeding
             protocol-specified limits

          -  Subjects with hepatic disease: child-puge score greater than 9; hepatic carcinoma and
             hepatorenal syndrome;Undergone porta-caval shunt surgery; History of GI hemorrhage due
             to esophageal varices or peptic ulcers less than 1 month prior to study entry;
             significant hepatic encephalopathy; severe ascites and/or pleural effusion; Positive
             blood alcohol test/alcohol breathalyzer at screening or on Day 0.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5351029&amp;StudyName=Study%20Examining%20The%20Effect%20Of%20Hepatic%20Impairment%20On%20Safety%2C%20Toleration%20And%20How%20The%20Body%20Processes%20An%20Experimental%20Drug</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2008</study_first_submitted>
  <study_first_submitted_qc>March 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2008</study_first_posted>
  <disposition_first_submitted>August 26, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>August 11, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 13, 2009</disposition_first_posted>
  <last_update_submitted>August 26, 2009</last_update_submitted>
  <last_update_submitted_qc>August 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

